Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

Presentation TCT 2025

Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial

Presenter: Upendra Kaul

October 28, 2025

Presentation TCT 2025

Tuxedo-II trial : Supraflex Cruz vs Xience Family stents comparison

Presenter: Upendra Kaul

October 28, 2025

Presentation TCT 2025

TCT 999: One- versus three-month DAPT in patients at high or very high bleeding risk undergoing PCI: Results from the XIENCE Short DAPT Program

Presenter: Davide Cao

October 27, 2025

Presentation TCT 2023

TCT 606: Alterations in the Endothelial Wall Shear Stress Due to the Presence of the Stent Footprint: Comparison Between Xience and Resolute Stent Platforms

Presenter: Imran Shah

October 25, 2023

Presentation TCT 2022

TCT 60: The impact of implantation techniques in Absorb BVS and Xience EES on lesion oriented-outcomes at complete five-year follow-up – an AIDA trial QCA substudy

Presenter: Mick Renkens

September 17, 2022

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

Presentation TCT 2020

TCT 167: Comparison of Stent Expansion Between Xience and Orsiro Stents in Heavily Calcified Coronary Arteries in Cadaver Heart

Presenter: Yu Sato

October 14, 2020

Presentation TCT 2019

The ABILITY DIABETES GLOBAL Imaging Study (Randomized Control Trial Comparing Abluminus DES vs. Xience)

Presenter: Azeem Latib

September 28, 2019

Presentation TCT 2019

The Science Behind Xience: From EXCEL to Short DAPT

Presenter: Sripal Bangalore

September 28, 2019

Presentation TCT 2019

XIENCE/ ONYX Short DAPT Programs

Presenter: Mitchell Krucoff

September 27, 2019

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Pieter C. Smits

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini

October 30, 2016

Presentation TCT 2015

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Presenter: Stephen G. Ellis, Patrick W. Serruys, Davide Capodanno

October 14, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Presentation TCT 2013

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Presenter: Yuejin Yang

October 29, 2013

Advertisement

Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial

Tuxedo-II trial : Supraflex Cruz vs Xience Family stents comparison

TCT 999: One- versus three-month DAPT in patients at high or very high bleeding risk undergoing PCI: Results from the XIENCE Short DAPT Program

TCT 606: Alterations in the Endothelial Wall Shear Stress Due to the Presence of the Stent Footprint: Comparison Between Xience and Resolute Stent Platforms

TCT 60: The impact of implantation techniques in Absorb BVS and Xience EES on lesion oriented-outcomes at complete five-year follow-up – an AIDA trial QCA substudy

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

TCT 167: Comparison of Stent Expansion Between Xience and Orsiro Stents in Heavily Calcified Coronary Arteries in Cadaver Heart

The ABILITY DIABETES GLOBAL Imaging Study (Randomized Control Trial Comparing Abluminus DES vs. Xience)

The Science Behind Xience: From EXCEL to Short DAPT

XIENCE/ ONYX Short DAPT Programs

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content